Home > Healthcare & Medical Devices > Uveitis Treatment Market

Uveitis Treatment Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028

  • Report ID: GMI4080

Uveitis Treatment Market size is projected to experience significant growth from 2022 to 2028. This is mainly attributed to the availability of numerous treatments depending on the severity of symptoms and the speed of recovery. According to studies, uveitis at the back of the eye tends to heal more slowly as compared to uveitis in the front of the eye. The industry growth is impelled by the increasing number of treatments for the reduction of inflammation in eyes and in other parts of the body, if these areas are impacted by uveitis.
 

The market is set to register commendable share from the anterior uveitis segment through 2028. The condition constitutes one of the most common types of ocular inflammation that could be encountered by eye care practitioners. As per statistics, uveitis accounts for nearly 10% of the legal blindness in the U.S. and could affect all age groups. The rising prevalence of anterior uveitis – which could be either chronic, subacute, or acute – is expected to boost segment expansion in the coming years.
 

On the basis of treatment type, the corticosteroids segment is estimated to depict substantial revenue from overall market share up to 2028. This is primarily on account of the increasing preference for corticosteroids for the treatment of posterior segment uveitis. Potent immunosuppressive and anti-inflammatory agents, corticosteroids inhibit phospholipase A2 and the production of leukotrienes and prostaglandins.
 

These steroids are in high demand owing to their ability to stabilize the blood-retina barrier by impacting the expression of certain molecules that are involved in water and ion flux. Additionally, they also help in the enhancement of tight junction integrity, in turn making them good agents for the reduction of macular edema.
 

North America uveitis treatment market size is poised to record lucrative expansion during the forecast period. The regional growth is credited to an increase in product developments by various companies. For instance, in October 2021, the U.S. FDA approved XIPERE (triamcinolone acetonide injectable suspension) for the treatment of macular edema, that is associated with uveitis, by means of suprachoroidal administration. Secured by Bausch + Laumb, this is the first approval that has been indicated for a treatment of ophthalmic disease by means of suprachoroidal pathway situated in the back of the eye.
 

Major players across the market comprise Novartis AG, Bausch & Lomb, EyePoint Pharmaceuticals, ALLERGAN, Wize Pharma Inc., Santen Pharmaceutical Co., Ltd., EyeGate, Alimera Sciences, Enzo Biochem Inc., Regeneron Pharmaceuticals, Alcon Inc. These companies are taking keen interest in the implementation of strategic initiatives including mergers, acquisitions, partnerships, and collaborations for fostering their position in the market.
 

For instance, in December 2021, EyeGate Pharmaceuticals acquired privately-held clinical stage biotech company, Panoptes Pharma, which is centered on the development of a novel proprietary small molecule for treating a range of eye diseases with a high unmet medical need.
 

Impact of COVID-19 on uveitis treatment market outlook

The COVID-19 pandemic has impacted the market in the form of disrupted care patterns, leading to potential disease management changes across a range of therapeutic areas. During the early period, ophthalmology was one of the most impacted specialties in the field of medicine, with severe curtailing of some practices and permission for carrying out only the most urgent procedures. Research states that patients of uveitis could be at higher risk of contracting COVID-19 when compared with the general population, suffering a more severe course of coronavirus. Owing to these factors, the industry is predicted to witness a steady demand for uveitis treatment drugs across various regions.
 

The market research report of uveitis treatment includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:

Market, by Type

  • Anterior uveitis
  • Posterior uveitis
  • Intermediate uveitis
  • Panuveitis  

Market, by Treatment

  • Immunosuppressive Medications
  • Antibiotic/Antiviral Medications
  • Anti-inflammatory Medications

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
       

What Information does this report contain?

Historical data coverage: 2017 to 2021; Growth Projections: 2022 to 2028.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Budget constraints? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability